Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cerus Corp (CERS)

Cerus Corp (CERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cerus Corp 1220 CONCORD AVENUE SUITE 600 CONCORD CA 94520 USA

www.cerus.com P: 925-288-6000

Description:

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.

Key Statistics

Overview:

Market Capitalization, $K 324,497
Enterprise Value, $K 392,647
Shares Outstanding, K 181,283
Annual Sales, $ 186,800 K
Annual Net Income, $ -37,490 K
Last Quarter Sales, $ 53,340 K
Last Quarter Net Income, $ -1,330 K
EBIT, $ -30,050 K
EBITDA, $ -27,450 K
60-Month Beta 1.31
% of Insider Shareholders 7.05%
% of Institutional Shareholders 78.37%
Float, K 168,503
% Float 92.95%
Short Volume Ratio 0.31

Growth:

1-Year Return -32.26%
3-Year Return -70.56%
5-Year Return -72.50%
5-Year Revenue Growth 145.63%
5-Year Earnings Growth 54.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 03/05/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -0.20
EPS Growth vs. Prev Qtr 66.67%
EPS Growth vs. Prev Year 87.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CERS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -67.17%
Return-on-Assets % -17.68%
Profit Margin % -20.07%
Debt/Equity 1.49
Price/Sales 2.02
Price/Cash Flow N/A
Price/Book 5.93
Book Value/Share 0.29
Interest Coverage -3.45
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar